Skip to main content
. 2022 Jun 24;7:198. doi: 10.1038/s41392-022-01042-7

Table 5.

Selective clinical trials of PARP inhibitors

Drug Target Condition Status Phase NCT identifier
Olaparib (AZD2281) PARPs PCa Completed 1 NCT02324998
Olaparib (AZD2281) PARPs mCRPC Not yet recruiting 3 NCT03732820
Olaparib (AZD2281) PARPs mCRPC Not yet recruiting 3 NCT02987543
Olaparib (AZD2281) PARPs mCRPC Not yet recruiting 3 NCT03834519
Rucaparib (AG014699) PARPs HR deficient mCRPC Completed 2 NCT02952534
Rucaparib (AG014699) PARPs mCRPC Not yet recruiting 3 NCT02975934
Veliparib (ABT-888) PARPs mCRPC Completed 2 NCT01576172
Talazoparib (BMN 673) PARPs HR deficient mCRPC Not yet recruiting 2 NCT03148795
Talazoparib (BMN 673) PARPs mCRPC Recruiting 3 NCT03395197
Niraparib (MK-4827) PARP1/2 mCRPC Completed 1 NCT02924766
Niraparib (MK-4827) PARP1/2 mCRPC Recruiting 3 NCT04497844
Pamiparib (BGB-290) PARP1/2 mCRPC Terminated 2 NCT03712930
Pamiparib (BGB-290) PARP1/2 mCRPC Not yet recruiting 1 NCT03150810